Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATALYST: Mifepristone for Hypercortisolism in Difficult-to-Control Type 2 Diabetes
NCT05772169Phase 4Completed
- Sponsor
- Corcept Therapeutics
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Cushing's syndrome comparing Mifepristone with Placebo (2 arms). Primary endpoints: Prevalence of Hypercortisolism, Effect of Treatment on Hypercortisolism with Abnormal Adrenal CT Scan at Week 24 and 1 more. Started Mar 2023; status: completed.
02
Drugs
mifepristone
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT05772169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05772169.